Language Processing and TMS
Launched by MEDICAL COLLEGE OF WISCONSIN · Jun 16, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Language Processing and TMS," is studying how a treatment called Transcranial Magnetic Stimulation (TMS) affects people who have had a stroke and struggle with language, a condition known as aphasia. The goal is to see if TMS can help improve language skills in these individuals, as well as in healthy participants for comparison. The study is currently looking for volunteers aged 18 and older, who are right-handed, fluent in English, and have had a stroke on the left side of their brain at least one month ago.
If you or a family member are interested in participating, it's important to know that certain medical conditions may prevent eligibility. For instance, individuals with severe cognitive or sensory impairments, unstable psychiatric conditions, or specific medical devices (like pacemakers) cannot take part. During the trial, participants can expect to undergo language and cognitive testing to assess the effects of TMS. This research could provide valuable insights into improving language recovery after a stroke, helping many people regain their communication skills.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with left hemisphere stroke
- • Consent date \>= 1 month after stroke onset
- • Right-handed
- • Fluent in English
- • 18 years of age or older
- Exclusion Criteria:
- • Severe cognitive, auditory or visual impairments that would preclude cognitive and language testing
- • Non-decisional per decisionality questionnaire or other clinical assessment
- • Presence of major untreated or unstable psychiatric disease (e.g. schizophrenia, bipolar disease)
- • A chronic medical condition that is not treated or is unstable
- • Presence of
- • 1. cardiac stimulators or pacemakers or intracardiac lines
- • 2. neurostimulators
- • 3. medication infusion device
- • 4. any other implants near the scalp (e.g., cochlear implants) or in the eye
- • 5. metal in the body
- • Pregnancy
- • History of skull fractures, or skin diseases
- • History of ongoing or unmanaged seizures or a family history of epilepsy
- • Presence of factors that potentially decrease seizure thresholds
- • On pro-convulsant medications
- • Untreated Sleep deprivation or insomnia
- • Ongoing alcoholism or illegal drug abuse (e.g., cocaine or MDMA users)
- • History of dyslexia or other developmental learning disabilities
About Medical College Of Wisconsin
The Medical College of Wisconsin (MCW) is a leading academic institution dedicated to advancing healthcare through innovative research, education, and clinical practice. As a prominent clinical trial sponsor, MCW is committed to conducting high-quality, ethically-guided research that aims to improve patient outcomes and address critical health challenges. Leveraging a multidisciplinary approach, MCW collaborates with a diverse network of healthcare professionals, researchers, and community partners to facilitate groundbreaking clinical trials across various medical fields, ensuring the translation of scientific discoveries into effective treatments and practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milwaukee, Wisconsin, United States
Patients applied
Trial Officials
Priyanka Shah-Basak, PhD
Principal Investigator
Medical College of Wisconsin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials